Keywords: methylnaltrexone, nda, sees, 3-month, extension, progenics, pharmaceuticals

Methylnaltrexone NDA sees 3-month extension

Article | 21 January 2008

Print This

Progenics Pharmaceuticals and fellow USA-based Wyeth say that the Food and Drug Administration has extended the review of their New ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in